Advanced in Fibrosing Mediastinitis

David Montani

Paris, FR 
Advanced in Fibrosing Mediastinitis
Paris, FR 
OverviewLocationsClinical Research

Overview

David Montani practices in Paris, France. Mr. Montani is rated as an Advanced expert by MediFind in the treatment of Fibrosing Mediastinitis. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Hypertension, Lung Transplant, and Angioplasty.

His clinical research consists of co-authoring 421 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Fibrosing Mediastinitis.

Gender
Male

Locations

Paris, France
Other Locations
Le Kremlin Bicêtre, France
Le Plessis, France
Raray, France
Gif-sur-yvette, France
78 Rue Du Général Leclerc, Le Kremlin Bicêtre, Rouez, 94270, France
157, Rue De La Porte De Trivaux, Clamart, 92140, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension
Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
View 2 Less Clinical Trials

421 Total Publications

Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study.
Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study.
Journal: American journal of respiratory and critical care medicine
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Montani's expertise for a condition
ConditionClose
View All 28 Advanced Conditions
View All 62 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile